Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market Share

Report ID: GMI10860
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Immune Checkpoint Inhibitors Market Share

The competitive landscape of the market is characterized by intense rivalry among leading pharmaceutical companies and biotech firms. Major players such as Bristol-Myers Squibb, Merck & Co., and Roche dominate the market with their flagship products like Opdivo, Keytruda, and Tecentriq, respectively. These companies are heavily investing in ongoing clinical trials and research to expand the indications for their existing therapies and develop novel checkpoint inhibitors.

Additionally, emerging biotech firms are entering the market with innovative approaches and novel targets, contributing to a dynamic and rapidly evolving competitive environment. Strategic collaborations, mergers and acquisitions, and significant investments in research and development are key strategies employed by these companies to maintain their competitive edge and drive growth in the market.

Immune Checkpoint Inhibitors Market Companies

Few of the prominent players operating in immune checkpoint inhibitors industry include:

AstraZeneca PLC
BeiGene, Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Incyte Corporation
Immutep Limited
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi
Shanghai Junshi Biosciences Co., Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Immune checkpoint inhibitors market size was USD 47.4 billion in 2023 and is expected to register 16.7% CAGR from 2024-2032 owing to increasing global cancer prevalence and a rising demand for advanced, personalized cancer therapies worldwide.

The PD-1 segment reached USD 34.7 billion by 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its pivotal role in cancer immunotherapy.

North America immune checkpoint inhibitors industry is expected to register 16.8% CAGR from 2024-2032 due to the presence of leading pharmaceutical companies, actively engaged in both the development and commercialization of immune checkpoint inhibitors in the region.

Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Incyte Corporation, Immutep Limited, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Sanofi, and Shanghai Junshi Biosciences Co., Ltd., are some of the major immune checkpoint inhibitors companies worldwide.